
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.71 | 1.71 | 1.71 | 0 | 0 | CS |
4 | 0 | 0 | 1.71 | 1.71 | 1.71 | 0 | 0 | CS |
12 | -1.85 | -51.9662921348 | 3.56 | 3.76 | 1.35 | 12364 | 1.90507738 | CS |
26 | -3.84 | -69.1891891892 | 5.55 | 11.685 | 1.35 | 5917625 | 6.99614135 | CS |
52 | -24.69 | -93.5227272727 | 26.4 | 26.997 | 1.35 | 3227488 | 7.1949108 | CS |
156 | -380.79 | -99.5529411765 | 382.5 | 414 | 1.35 | 1182372 | 28.43967466 | CS |
260 | -3058.29 | -99.9441176471 | 3060 | 3285 | 1.35 | 1261451 | 893.04888638 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.